Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the ‘real-world’

Published: February 8, 2020
Category: Bibliography
Authors: Craig C. Earle, Lee Mozessohn, Matthew C. Cheung, Nicole Mittmann, Ning Liu, Rena Buckstein
Countries: Canada
Language: English
Types: chronic condition, Population Health, Utilization
Settings: Government


Despite the adoption of azacitidine (AZA) in higher-risk MDS/low-blast count AML, limited ‘real-world’ data on resource utilization and toxicity exist.


We linked the Ontario AZA-MDS registry to population-based administrative databases.


Among 877 patients in the registry, 705 (80.4%) had at least one emergency department (ED) visit, 290 (33.1%) had an ED visit during their first cycle and 680 patients (77.5%) had at least one hospitalization (mean length 17.7 days, 95% CI 16.3–19.1). Older age, rurality, non-response to AZA, transfusion dependence, IPSS score, and greater comorbidity were independent predictors of increased ED visits; while greater comorbidity, non-response to AZA, and transfusion dependence were associated with longer hospitalization. When restricted to receiving ≥3 cycles, hospitalization during the first cycle was associated with increased risk of death.


Our analysis of ‘real-world’ patients treated with AZA demonstrates significant healthcare utilization and increased risk of death for patients hospitalized during their first cycle. These results will inform patients/providers about ‘real-world’ toxicities of AZA.

Myelodysplastic syndromesmyeloid leukemiahealth servicesazacitidine

Please log in/register to access.

Log in/Register

LinkedIn Facebook Twitter

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System.
All rights reserved. Terms of Use Privacy Statement

Back to top